INDP übertreffen die 23 der letzten 39Schätzungen.
59%
Nächster Bericht
Datum des nächsten Berichts
10. März 2026
Estimate forQ4 25(Revenue/ EPS)
--
/
-$4.44
Implizierte Änderung vonQ3 25(Revenue/ EPS)
--
/
+48.99%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
--
/
-58.27%
Indaptus Therapeutics, Inc. Common Stock earnings per share and revenue
On 12. Nov. 2025, INDP reported earnings of -2.98 USD per share (EPS) for Q3 25, beating the estimate of -4.25 USD, resulting in a 29.94% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +6.25% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -4.44 USD, with revenue projected to reach -- USD, implying an increase of 48.99% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Pharmaceuticals Inc. Common
Report Date
26. Dez. 2025 For Q4 25
Estimate
-$0.49
Aktuell
-
Überraschung
-
FAQ
What were Indaptus Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Indaptus Therapeutics, Inc. Common Stock reported EPS of -$2.98, beating estimates by 29.94%, and revenue of $0.00, 0% as expectations.
How did the market react to Indaptus Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 6.25%, changed from $2.72 before the earnings release to $2.89 the day after.
When is Indaptus Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 10. März 2026.
What are the forecasts for Indaptus Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analysts, Indaptus Therapeutics, Inc. Common Stock is expected to report EPS of -$4.44 and revenue of -- for Q4 2025.